Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent
Open Access
- 1 February 2008
- journal article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 2, 49-59
- https://doi.org/10.2147/dddt.s2757
Abstract
Peer reviewed article authored by (Mark Welliver, John McDonough, Nicholas Kalynych, Robert Redfern). Read article or submit your manuscript for publishing.Keywords
This publication has 38 references indexed in Scilit:
- Sugammadex: Another Milestone in Clinical Neuromuscular PharmacologyAnesthesia & Analgesia, 2007
- A Temporary Decrease in Twitch Response During Reversal of Rocuronium-Induced Muscle Relaxation with a Small Dose of SugammadexAnesthesia & Analgesia, 2007
- Sugammadex Reversal of Rocuronium-Induced Neuromuscular Blockade: A Comparison with Neostigmine???Glycopyrrolate and Edrophonium???AtropineAnesthesia & Analgesia, 2007
- Reversal of Profound Rocuronium Neuromuscular Blockade by Sugammadex in Anesthetized Rhesus MonkeysAnesthesiology, 2006
- Drug delivery for optimised products: from product life-cycle management to first-generation product conceptsExpert Opinion on Drug Delivery, 2005
- Drugs, QTc Interval Prolongation and Final ICH E14 GuidelineDrug Safety, 2005
- Pharmaceutics for the anaesthetistAnaesthesia, 2001
- Hypertonic saline (7.5%) after coronary artery bypass graftingEuropean Journal of Anaesthesiology, 2001
- The Effects of Residual Neuromuscular Blockade and Volatile Anesthetics on the Control of VentilationAnesthesia & Analgesia, 1999
- Residual neuromuscular block is a risk factor for postoperative pulmonary complications A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuroniumActa Anaesthesiologica Scandinavica, 1997